An Open-label Study With a Nonrandomized Single-dose Phase in Subjects With Suspected or Confirmed Aerobic Gram-negative Bacterial Infections Followed by a Randomized, Multiple-dose, Active-controlled Phase in Subjects With Suspected or Confirmed Complicated Urinary Tract Infection (cUTI), Hospital-acquired Bacterial Pneumonia (HABP) or Ventilator-associated Bacterial Pneumonia (VABP) to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Subjects 3 Months to < 18 Years of Age
Latest Information Update: 30 May 2025
At a glance
- Drugs Cefiderocol (Primary) ; Antibacterials
- Indications Aerobic infections; Bacterial infections; Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Pneumonia; Sepsis; Urinary tract infections; Ventilator associated pneumonia
- Focus Adverse reactions; Pharmacokinetics
- Acronyms APEKS-PEDI
- Sponsors Shionogi
Most Recent Events
- 15 Oct 2024 Status changed from active, no longer recruiting to completed.
- 10 Sep 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2024 Planned End Date changed from 15 Jun 2024 to 30 Sep 2024.